Latest Incentive Payments News

Opthea Limited has streamlined its operations with a NASDAQ delisting and completed a strategic review, positioning itself to advance the OPT-302 treatment for LAM with a robust cash position.

Advanced Braking Technology Ltd reports a robust Q2 FY26 with a 34% increase in product sales revenue and a 191% jump in net profit before tax, underpinned by strong international expansion and domestic contract wins.

ClearVue Technologies has secured an A$881k Australian Government R&D rebate and used part of it to retire a A$409k loan, strengthening its financial position as it advances its solar glass technology.

TerraCom Limited reports a $43.4 million net loss for FY25, reflecting increased impairment charges and operational challenges, while advancing its strategic Moorlands Project in Australia.

Iress Limited has appointed Andrew Russell as its new Group CEO, marking a strategic leadership shift following a major company transformation. Russell’s extensive fintech experience positions him to lead Iress into a product and client-focused future.

Praemium Limited reported robust FY25 results with revenue climbing 24.6% to $103 million and net profit after tax soaring 55% to $13.56 million, underpinned by strong growth in funds under administration and strategic product launches.

Monash IVF Group reported a 6.7% revenue increase to $271.9 million in FY25 but saw an 8.1% decline in underlying net profit after tax to $27.4 million, impacted by market softness and operational incidents. The company outlines cautious FY26 guidance amid ongoing sector headwinds.

Austal Limited has finalized a Strategic Shipbuilding Agreement with the Commonwealth of Australia, positioning its subsidiary as the nation’s key Tier 2 naval shipbuilder. This long-term pact sets the stage for significant defence vessel construction in Western Australia.

Alcidion Group Limited has reported its strongest quarter ever with record operating cashflow and a doubling of new sales, reaffirming its positive outlook for FY25.

Percheron Therapeutics has discontinued its ATL1103 program and curtailed investment in ATL1102 following underwhelming trial results, while advancing talks to in-license new rare disease therapies and extending its cash runway into FY2027.

Entyr Limited has received a $3.79 million R&D tax incentive payment for its innovative thermal desorption project targeting rubber waste, reinforcing its position in sustainable tyre recycling technology.

Alexium International Group reports a 16% sales increase in Q2 FY25 despite ongoing mattress market softness, driven by strategic product diversification and supply chain improvements.